| Characteristic . | All patients (n = 35)* . | >2–3 cm (n = 5) . | >3–4 cm (n = 18)# . | >4–6 cm (n = 13)# . |
|---|---|---|---|---|
| Age, median (range), y | 63 (25-76) | 67 (56-72) | 63.5 (34-76) | 63 (25-72) |
| Sex | ||||
| Female | 23 (66%) | 4 | 12 | 7 |
| Male | 12 (34%) | 1 | 6 | 6 |
| Race | ||||
| White | 28 (80%) | 4 | 18 | 7 |
| Other | 7 (20%) | 1 | 0 | 6 |
| Primary cancer | ||||
| Non-small cell lung cancer | 20 (57%) | 4 | 9 | 8 |
| Breast cancer | 5 (14%) | 1 | 3 | 1 |
| Colon cancer | 3 (9%) | 0 | 1 | 2 |
| Esophageal cancer | 3 (9%) | 0 | 2 | 0 |
| Endometrial cancer | 2 (5%) | 0 | 1 | 2 |
| Melanoma | 1 (3%) | 0 | 1 | 0 |
| Prostate cancer | 1 (3%) | 0 | 1 | 0 |
| KPS | ||||
| 90 | 6 (17%) | 0 | 3 | 2 |
| 80 | 17 (49%) | 5 | 7 | 6 |
| 70 | 11 (31%) | 0 | 7 | 5 |
| 60 | 1 (3%) | 0 | 1 | 0 |
| Characteristic . | All patients (n = 35)* . | >2–3 cm (n = 5) . | >3–4 cm (n = 18)# . | >4–6 cm (n = 13)# . |
|---|---|---|---|---|
| Age, median (range), y | 63 (25-76) | 67 (56-72) | 63.5 (34-76) | 63 (25-72) |
| Sex | ||||
| Female | 23 (66%) | 4 | 12 | 7 |
| Male | 12 (34%) | 1 | 6 | 6 |
| Race | ||||
| White | 28 (80%) | 4 | 18 | 7 |
| Other | 7 (20%) | 1 | 0 | 6 |
| Primary cancer | ||||
| Non-small cell lung cancer | 20 (57%) | 4 | 9 | 8 |
| Breast cancer | 5 (14%) | 1 | 3 | 1 |
| Colon cancer | 3 (9%) | 0 | 1 | 2 |
| Esophageal cancer | 3 (9%) | 0 | 2 | 0 |
| Endometrial cancer | 2 (5%) | 0 | 1 | 2 |
| Melanoma | 1 (3%) | 0 | 1 | 0 |
| Prostate cancer | 1 (3%) | 0 | 1 | 0 |
| KPS | ||||
| 90 | 6 (17%) | 0 | 3 | 2 |
| 80 | 17 (49%) | 5 | 7 | 6 |
| 70 | 11 (31%) | 0 | 7 | 5 |
| 60 | 1 (3%) | 0 | 1 | 0 |
*Unless otherwise indicated, data were presented as number (percentage) of patients.
#1 patient with 2 lesions was enrolled in 15 Gy of >3–4 cm cohort and 12 Gy of >4–6 cm cohort at the same time.
| Characteristic . | All patients (n = 35)* . | >2–3 cm (n = 5) . | >3–4 cm (n = 18)# . | >4–6 cm (n = 13)# . |
|---|---|---|---|---|
| Age, median (range), y | 63 (25-76) | 67 (56-72) | 63.5 (34-76) | 63 (25-72) |
| Sex | ||||
| Female | 23 (66%) | 4 | 12 | 7 |
| Male | 12 (34%) | 1 | 6 | 6 |
| Race | ||||
| White | 28 (80%) | 4 | 18 | 7 |
| Other | 7 (20%) | 1 | 0 | 6 |
| Primary cancer | ||||
| Non-small cell lung cancer | 20 (57%) | 4 | 9 | 8 |
| Breast cancer | 5 (14%) | 1 | 3 | 1 |
| Colon cancer | 3 (9%) | 0 | 1 | 2 |
| Esophageal cancer | 3 (9%) | 0 | 2 | 0 |
| Endometrial cancer | 2 (5%) | 0 | 1 | 2 |
| Melanoma | 1 (3%) | 0 | 1 | 0 |
| Prostate cancer | 1 (3%) | 0 | 1 | 0 |
| KPS | ||||
| 90 | 6 (17%) | 0 | 3 | 2 |
| 80 | 17 (49%) | 5 | 7 | 6 |
| 70 | 11 (31%) | 0 | 7 | 5 |
| 60 | 1 (3%) | 0 | 1 | 0 |
| Characteristic . | All patients (n = 35)* . | >2–3 cm (n = 5) . | >3–4 cm (n = 18)# . | >4–6 cm (n = 13)# . |
|---|---|---|---|---|
| Age, median (range), y | 63 (25-76) | 67 (56-72) | 63.5 (34-76) | 63 (25-72) |
| Sex | ||||
| Female | 23 (66%) | 4 | 12 | 7 |
| Male | 12 (34%) | 1 | 6 | 6 |
| Race | ||||
| White | 28 (80%) | 4 | 18 | 7 |
| Other | 7 (20%) | 1 | 0 | 6 |
| Primary cancer | ||||
| Non-small cell lung cancer | 20 (57%) | 4 | 9 | 8 |
| Breast cancer | 5 (14%) | 1 | 3 | 1 |
| Colon cancer | 3 (9%) | 0 | 1 | 2 |
| Esophageal cancer | 3 (9%) | 0 | 2 | 0 |
| Endometrial cancer | 2 (5%) | 0 | 1 | 2 |
| Melanoma | 1 (3%) | 0 | 1 | 0 |
| Prostate cancer | 1 (3%) | 0 | 1 | 0 |
| KPS | ||||
| 90 | 6 (17%) | 0 | 3 | 2 |
| 80 | 17 (49%) | 5 | 7 | 6 |
| 70 | 11 (31%) | 0 | 7 | 5 |
| 60 | 1 (3%) | 0 | 1 | 0 |
*Unless otherwise indicated, data were presented as number (percentage) of patients.
#1 patient with 2 lesions was enrolled in 15 Gy of >3–4 cm cohort and 12 Gy of >4–6 cm cohort at the same time.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
